A case of acute profound thrombocytopenia following abciximab therapy.
- Author:
Jin Woo KIM
1
;
Seon Ho LEE
;
Seung Ryul KIM
;
Jong Ho PARK
;
Yung Joo MIN
;
Jae Hoo PARK
Author Information
1. Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea.
- Publication Type:Case Report
- Keywords:
Abciximab;
Thrombocytopenia
- MeSH:
Angioplasty;
Hemorrhage;
Humans;
Incidence;
Injections, Intravenous;
Ischemia;
Middle Aged;
Myocardial Infarction;
Platelet Count;
Thrombocytopenia*
- From:Korean Journal of Medicine
2002;62(4):475-481
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bleeding and thrombocytopenia are important adverse effects of abciximab. The incidence of abciximab-induced acute profound thrombocytopenia (APT) is low. APT is defined as an abrupt drop in platelet count to <20,000/microL that occurred within 24 hours of administration of an abciximab. This is distinct from all other types of drug-induced thrombocytopenia, which requires a period of drug administration to induce sensitization. If APT occurs and is left untreated, it can cause serious hemorrhage and ischemia that may be fatal. In this case, a 45-year-old man with acute myocardial infarction was administered a bolus intravenous injection of abciximab (0.25 mg/kg), followed by a 12-hour continuous infusion (10 microgram/min) during primary coronary angioplasty. We report a case of APT that was recognized at 2 hours after the initiation of abciximab infusion and was corrected without serious complications.
